Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada

Author(s)

Vilches, Thomas N. ; Zhang, Kevin ; Van Exan, Robert ; Langley, Joanne M. ; Moghadas, Seyed M.

• Document type: Journal article
• Source: Vaccine; v. 39, n. 17, p. 6-pg., 2021-04-11.

Abstract

Background: A number of highly effective COVID-19 vaccines have been developed and approved for mass vaccination. We evaluated the impact of vaccination on COVID-19 outbreak and disease outcomes in Ontario, Canada. Methods: We used an agent-based transmission model and parameterized it with COVID-19 characteristics, demographics of Ontario, and age-specific clinical outcomes. We implemented a two-dose vaccination program according to tested schedules in clinical trials for Pfizer-BioNTech and Moderna vaccines, prioritizing healthcare workers, individuals with comorbidities, and those aged 65 and older. Daily vaccination rate was parameterized based on vaccine administration data. Using estimates of vaccine efficacy, we projected the impact of vaccination on the overall attack rate, hospitalizations, and deaths. We further investigated the effect of increased daily contacts at different stages during vaccination campaigns on outbreak control. Results: Maintaining non-pharmaceutical interventions (NPIs) with an average of 74% reduction in daily contacts, vaccination with Pfizer-BioNTech and Moderna vaccines was projected to reduce hospitalizations by 27.3% (95% CrI: 22.3% - 32.4%) and 27.0% (95% CrI: 21.9% - 32.6%), respectively, over a oneyear time horizon. The largest benefits of vaccination were observed in preventing deaths with reductions of 31.5% (95% CrI: 22.5% - 39.7%) and 31.9% (95% CrI: 22.0% - 41.4%) for Pfizer-BioNTech and Moderna vaccines, respectively, compared to no vaccination. We found that an increase of only 10% in daily contacts at the end of lockdown, when vaccination coverage with only one dose was 6%, would trigger a surge in the outbreak. Early relaxation of population-wide measures could lead to a substantial increase in the number of infections, potentially reaching levels observed during the peak of the second wave in Ontario. Conclusions: Vaccination can substantially mitigate ongoing COVID-19 outbreaks. Sustaining populationwide NPIs, to allow for a sufficient increase in population-level immunity through vaccination, is essential to prevent future outbreaks. (C) 2021 The Author(s). Published by Elsevier Ltd. (AU)

• FAPESP's process: 18/24811-1 - Mathematical modelling for the transmission of schistosomiasis in low-prevalence areas
• Grantee: Thomas Nogueira Vilches
• Support Opportunities: Scholarships in Brazil - Post-Doctoral